Top 50 Ai For Drug Discovery in Latin America

Nintx Next Innovative Therapeutics utilizes proprietary technologies such as xGIbiomics, which simulates the human gastrointestinal system, and GAIApath, an AI-driven analytics platform, to identify and develop plant-based therapies targeting multifactorial diseases. By leveraging Brazil's rich biodiversity, Nintx aims to create multi-target therapies that modulate human biological systems and the microbiome, addressing the limitations of traditional single-target drug approaches.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.

The startup specializes in identifying bioactive ribonucleic acid (RNA) from natural sources using machine learning and bioinformatics techniques. This enables researchers to enhance human health and resilience in response to environmental stressors through the application of RNA technologies.

The startup develops personalized pharmaceutical technology that tailors medication regimens based on individual patient profiles, enhancing therapeutic efficacy and minimizing adverse effects. By utilizing advanced data analytics and pharmacogenomics, the company aims to improve patient outcomes and overall quality of life.

Onc.AI develops an AI-powered clinical management platform that utilizes a comprehensive oncology real-world dataset, including diagnostic imaging and genomics, to enhance treatment decision-making for metastatic lung cancer patients undergoing PD-1 immunotherapy. The platform provides actionable insights that enable oncologists to improve patient outcomes by optimizing treatment strategies based on real-world evidence.

Provides data science, machine learning, and artificial intelligence consulting to help organizations in Colombia and LATAM leverage data for improved decision-making, operational efficiency, and cost reduction. Specializes in developing predictive models, optimizing processes, and implementing AI strategies tailored to industries such as healthcare, finance, agriculture, and retail.

Precision Data provides a business intelligence platform that utilizes generative artificial intelligence to optimize access to over 8 billion lines of structured clinical data, enhancing real-world evidence studies in healthcare. The company addresses the challenge of data quality and accessibility, enabling healthcare organizations to make informed decisions based on accurate and comprehensive information.

Omni is a digital pharmacy application that provides a flexible medication plan usable at any pharmacy in Brazil, allowing users to manage their health expenses through a simple app interface. The platform utilizes artificial intelligence to interpret medical prescriptions and offers professional health guidance, reducing treatment abandonment and improving chronic condition management for employees.

CellRep develops cell reprogramming strategies to enhance T cell functionality, increasing their therapeutic potential for cancer and chronic conditions. The company provides an end-to-end pipeline from target discovery to preclinical validation, enabling more effective cell therapies for patients.

Proffer is a platform that utilizes artificial intelligence and data science to automate price and discount management for the pharmaceutical retail and distribution sectors. By providing real-time market and competitor data, it enables businesses to optimize pricing strategies, enhancing profitability and competitiveness.

Onward Assist is a predictive analytics platform that utilizes AI-driven image analysis to enhance cancer diagnosis by identifying biomarkers and reducing reporting time by 30-40%. The platform addresses the lack of effective cancer scoring tools tailored for diverse populations, enabling pathologists to make more accurate treatment decisions efficiently.

Develops senoblockers, a novel class of therapeutics that target epigenetic regulators to reverse cellular senescence and restore stem cell activity. This approach addresses the decline in regenerative capacity and the accumulation of senescent cells, which are key contributors to age-related diseases.

CuraSen Therapeutics develops orphan drugs targeting neurodegenerative diseases by utilizing advanced pharmacological approaches to enhance neuroprotection and promote neuronal health. The company focuses on addressing the unmet medical needs of patients suffering from conditions like Alzheimer's and Parkinson's, where current treatment options are limited.

The startup is developing a Clinical Digital Twin Platform that creates virtual replicas of patients using real-time health data and advanced modeling techniques. This platform enables healthcare providers to personalize treatment plans and improve patient outcomes by simulating various clinical scenarios.

metaBIX Biotech has developed a platform that utilizes hardware, biotechnology, and artificial intelligence to monitor airborne pathogens, providing early warnings of potential disease outbreaks in plants, animals, and humans. This technology enables clients to implement preventive measures at least two weeks before an outbreak occurs, enhancing safety and public health.

Guska develops synthetic RNA oncolytic virus therapies that precisely target and eliminate cancer cells while stimulating the immune system. This approach offers a more effective and less harmful alternative to traditional cancer treatments by enhancing the body's ability to fight tumors.

Ambient Scientific develops the GPX10, an ultra-low power AI microprocessor designed for on-device applications, enabling years of operation on a single coin cell battery. This technology addresses the limitations of cloud dependency by providing efficient, always-on AI capabilities for battery-powered edge devices, enhancing data privacy and reducing operational costs.

EnCharge AI develops a scalable analog in-memory computing platform that enhances AI performance by achieving 20 times higher efficiency and 10 times lower total cost of ownership compared to traditional GPU solutions. This technology enables on-device processing, significantly reducing CO2 emissions and ensuring data privacy while making advanced AI accessible beyond cloud infrastructure.

D-Matrix has developed Corsair, an AI inference platform that achieves 60,000 tokens per second with 1 ms latency for Llama3 8B models, significantly enhancing throughput and energy efficiency in datacenters. This technology addresses the high computational costs and energy consumption associated with large-scale AI inference, enabling organizations to scale their AI capabilities sustainably.

Gennie is a generative AI platform that accelerates the product development process by over 10 times, utilizing advanced methodologies in Design Thinking and innovation processes. It addresses the lengthy time-to-market challenge by refining concepts early in the development cycle, enabling businesses to validate ideas more efficiently.

Huna develops an AI engine that analyzes routine blood test data to identify risk patterns for early cancer detection and other chronic diseases. This technology enables healthcare providers to classify patients by risk level, improving clinical decision-making and increasing the chances of successful treatment while reducing overall healthcare costs.

SHS Health Tech utilizes artificial intelligence to connect healthcare institutions with suppliers of medical supplies and pharmaceuticals, optimizing procurement processes through data-driven insights. This approach reduces acquisition costs and enhances supply chain efficiency, addressing the challenges of fragmented purchasing and inconsistent supplier relationships in the healthcare sector.

Arkangel AI is a no-code platform that transforms medical data into AI algorithms for early disease detection, enabling healthcare organizations to build and deploy tailored solutions efficiently. By streamlining processes such as patient triage and drug adverse effect prediction, Arkangel AI enhances healthcare outcomes while significantly reducing operational costs.

Rosebud Biosciences develops targeted therapies for rare genetic diseases in children by utilizing organoids that replicate specific genetic mutations, allowing for precise drug screening. This approach addresses the critical lack of approved treatments for 95% of rare diseases, significantly improving the potential for effective cures.

Aperture Therapeutics develops a drug discovery engine that utilizes extensive cell libraries representing genetic diversity to identify gene variants that confer protection against neurodegenerative diseases. By targeting specific RNA transcripts, the company aims to create therapies that can delay brain aging and improve outcomes for affected populations.

Terraflos utilizes synthetic biology and cellular agriculture to produce high-value bioactive compounds from plant genetic information and stem cells, minimizing environmental impact. The startup addresses the growing demand for sustainable health and wellness solutions by providing optimized active ingredients for the cosmetic, food, nutraceutical, and pharmaceutical industries.

The startup develops biological treatments using single-domain antibodies for targeted therapies, focusing on pre-clinical studies to validate therapeutic applications. Their advancements in delivery methods, including topical, inhalation, injectable, and oral administration, enable tailored treatments for specific medical conditions.

Kinzbio develops precision antimicrobial therapies using bacteriophages to target and eliminate specific bacterial pathogens. Their AI-driven platform rapidly identifies and optimizes phages for personalized treatments, offering a highly specific alternative to traditional antibiotics.

Provides an AI-powered platform for managing corporate innovation programs, integrating startups, industry federations, and corporate venture capital (CVC) to streamline processes, track performance, and generate automated reports. This platform enables corporations to execute strategic innovation plans, invest in early-stage startups, and foster collaboration within business ecosystems, reducing costs and accelerating time-to-market for new solutions.

Comsentimento develops an AI-driven platform for clinical data transformation and research, focusing on enhancing cancer treatment and facilitating access to clinical trials. The platform provides healthcare professionals with actionable insights and support for chronic disease management, improving patient care and treatment adherence.

Yeda Health utilizes artificial intelligence to provide personalized dietary and lifestyle recommendations based on individual responses to food and continuous glucose monitoring data. This approach addresses the challenge of managing blood glucose levels by recognizing that each person's metabolic response is unique, enabling tailored strategies for metabolic stability.

The startup has developed a clinical research platform that utilizes machine learning to target the biological processes of aging, facilitating the discovery of therapies for age-related diseases such as cardiovascular and neurodegenerative conditions. By enabling pharmaceutical companies to enhance medical treatments, the platform addresses the need for more effective interventions in aging-related health issues.

The startup offers a healthcare platform that utilizes artificial intelligence and data mining to enhance treatment management for patients and medical providers. By enabling patients to identify specialists and appropriate treatments, the platform improves diagnostic analysis and user experience, ultimately reducing the time and resources required for patient care.

Mundos provides a collaborative research platform that utilizes AI to analyze input topics and generate actionable insights, enabling professionals to capture and share tacit knowledge effectively. By transforming complex data into clear visualizations, Mundos enhances real-time teamwork and customizes outputs for tailored reporting.

Begen is a platform that connects businesses with specialized AI developers, enabling efficient access to AI solutions while reducing development costs. It addresses the challenge of AI adoption by providing a controlled environment for companies to implement AI-driven innovations and streamline their operations.

CytoEM Innovations decodes the electromagnetic identity of various cell types to precisely control their growth and behavior through interferometry. This technology addresses the challenges of low cell yield and high production costs in bioprocesses, enhancing efficiency in pharmaceutical and agricultural applications.

The startup develops chip technology that integrates big data analytics and heterogeneous computing to enhance the functionality of the Internet of Things. This technology enables industries, such as automotive and healthcare, to incorporate artificial intelligence into their products and services, improving operational efficiency and decision-making capabilities.

AIMedic utilizes artificial intelligence to integrate diverse medical data sources, enhancing diagnostic accuracy and treatment selection for healthcare professionals. The platform supports patient monitoring through an intelligent assistant, providing validated educational resources and vital health updates to improve patient outcomes.

This healthcare platform uses AI to analyze a patient's complete medical history, including medications and exam results, to generate intelligent diagnostic hypotheses. It helps medical professionals formulate accurate diagnoses by feeding patient characteristics into an algorithm, streamlining the diagnostic process.

Base Cientifica offers comprehensive molecular and cellular research services to accelerate preclinical development and personalized medicine. They specialize in biological assay validation, biobanking, and molecular diagnostic assay development using PCR and NGS. Their services also include preclinical efficacy and safety studies, 3D organoid cultivation, and AI-driven R&D optimization.

The startup offers an ecosystem of AI agent-based tools that enhance human capabilities by facilitating the design, execution, and monitoring of collaborative processes between humans and AI. This approach addresses the challenges of inefficient workflows and communication, enabling users to improve productivity and decision-making through increased cognitive support and skill development.

The startup operates a genomics platform that centralizes and integrates DNA data to provide precise diagnoses and personalized treatment plans through advanced data analysis and interpretation. By leveraging genomic information, the platform enables researchers to enhance health outcomes and preventive care strategies for individuals.

The startup develops AI-powered applications that enhance decision-making by analyzing large datasets and providing actionable insights. This technology enables organizations to make data-driven choices more efficiently, reducing uncertainty and improving operational outcomes.

Speratum Biopharma is developing targeted molecular therapeutics utilizing a proprietary RNA interference (RNAi) mimic of miR-198 for the treatment of solid tumors. The company's approach addresses the need for effective cancer therapies by enhancing the systemic and targeted delivery of oligonucleotides to inhibit tumor growth.

Celentis develops novel therapeutic solutions by leveraging advanced biotechnology research. The company focuses on creating innovative treatments for unmet medical needs, aiming to improve patient outcomes.

The startup utilizes a proprietary Generative Biology Platform and a Discovery Platform that integrate machine learning and multi-modal single-cell analysis to identify gene regulatory networks and develop targeted cell therapies for cancer. By precisely modulating gene expression in specific cell types, the company aims to enhance the efficacy of cell-based treatments, addressing the limitations of traditional cancer therapies.

Naturannova utilizes a computational platform that combines AI and bioinformatics to identify and analyze plant-based proteins, creating sustainable and clean label ingredients. The startup addresses the need for healthier food options by developing novel protein sources, such as their all-natural protein-based sweetener, through precision fermentation and laboratory testing.

This startup has developed a biotech platform that enhances the drug discovery process through predictive toxicology and drug quality assurance, specifically tailored for the Latin American market. By optimizing research and development workflows, the platform reduces time and costs while minimizing the reliance on animal testing.

Vortice.ai focuses on the integration of large language models (LLMs) with natural language processing (NLP) to enhance machine learning and generative AI applications. Their research and development efforts aim to create solutions that improve the efficiency and effectiveness of data retrieval and generation in artificial intelligence systems.

Mercury Bio has developed a proprietary chimeric extracellular vesicle (yEV™) platform that delivers ribonucleic acid and small-molecule drugs to specific cells, enhancing drug potency while minimizing side effects. This technology addresses the challenge of effective therapeutic delivery by enabling targeted treatment of viral diseases, cancer, and inflammatory conditions without triggering an immune response.